Sara Tolaney· @stolaney1 · X·· 2 天前评分90
正文 · 机器翻译
HORIZON-Breast06：Trastuzumab rezetecan用于转移性HER2low乳腺癌
n=551
化疗初治患者的PFS：16.6 vs 6.8个月，HR 0.25
PFS在HR+与HR-患者中一致（HR 0.34和HR 0.24）
OS数据尚未成熟
ILD 2.5%
@OncoAlert #ESMO2026
522 浏览 · 9 赞 · 9 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源：Sara Tolaney · x.com